In previous studies, patients with stage III/IV non-small-cell lung cancer (NSCLC) who developed irAEs after treatment with anti-PD-(L)1 ICIs alone or in combination with other anticancer agents had better overall and progression-free survival compared to those who did not develop irAEs [22]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.